阿司匹林治疗ARDS的随机安慰剂对照临床试验
这项在英国5个ICU开展的2期随机双盲安慰剂对照试验,因招募缓慢在入组49例(计划60例)后提前终止,评估肠溶阿司匹林75 mg每日一次对ARDS患者第7天氧合指数的影响。结果显示阿司匹林组与安慰剂组第7天氧合指数无显著差异,不良事件数量两组均为13例,阿司匹林耐受性良好但未改善氧合指数或其他生理结局。
要点
- 阿司匹林75 mg每日一次未显著改善ARDS患者第7天氧合指数。
- 两组不良事件数量均为13例,阿司匹林耐受性良好。
- 因招募缓慢试验提前终止,现有设计下更大规模试验不可行。
核心结论
- 阿司匹林耐受性良好,但未改善氧合指数或其他生理结局。
- 现有设计下开展更大规模试验不可行。
研究设计与样本
- 随机、双盲(患者和研究者)、分配隐藏、安慰剂对照的2期试验,在英国5个ICU开展。
- 符合柏林定义的ARDS患者按1:1随机分配接受肠溶阿司匹林75 mg或安慰剂,最长14天,按血管升压药需求分层。
主要发现
- 阿司匹林未显著影响次要结局。
- 不良事件数量两组均为13例(OR 1.04,95%CI 0.56-1.94,P=0.56)。
临床怎么用
- 不推荐对ARDS患者使用阿司匹林75 mg每日一次以改善氧合指数。
- 阿司匹林在该人群中耐受性良好,但现有证据不支持其作为ARDS的治疗选择。
局限性
- 试验因招募缓慢提前终止,实际入组49例低于计划的60例。
- 样本量小,可能影响检验效能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is no pharmacologic treatment for ARDS. Platelets play an important role in the pathophysiology of ARDS. Preclinical, observational, and clinically relevant models of ARDS indicate aspirin as a potential therapeutic option. RESEARCH QUESTION: Is enteral aspirin (75 mg, once daily) safe and effective in improving surrogate outcomes in adult patients with ARDS? STUDY DESIGN AND METHODS: This randomized, double-blind (patient and investigator), allocation-concealed, placebo-controlled phase 2 trial was conducted in five UK ICUs. Patients fulfilling the Berlin definition of ARDS were randomly assigned at a 1:1 ratio to receive enteral aspirin (75 mg) or placebo, for a maximum of 14 days, using a computer-generated randomization schedule, with variable block size, stratified by vasopressor requirement. The primary end point was oxygenation index (OI) on day 7. Secondary outcomes included safety parameters and other respiratory physiological markers. Analyses were by intention to treat. RESULTS: The trial was stopped early, due to slow recruitment, after 49 of a planned 60 patients were recruited. Twenty-four patients were allocated to aspirin and 25 to placebo. There was no significant difference in day 7 OI [aspirin group: unadjusted mean, 54.4 (SD 26.8); placebo group: 42.4 (SD 25); mean difference, 12.0; 95% CI, -6.1 to 30.1; P = .19]. Aspirin did not significantly impact the secondary outcomes. There was no difference in the number of adverse events between the groups (13 in each; OR, 1.04; 95% CI, 0.56-1.94; P = .56). INTERPRETATION: Aspirin was well tolerated but did not improve OI or other physiological outcomes; a larger trial is not feasible in its current design. TRIAL REGISTRATION: ClinicalTrials.gov; No.: NCT02326350; URL: www. CLINICALTRIALS: gov.
引用
- Toner P, Boyle AJ, McNamee JJ, et al. Aspirin as a Treatment for ARDS: A Randomized, Placebo-Controlled Clinical Trial. Chest. 2021. PMID: 34785236. doi:10.1016/j.chest.2021.11.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。